This suggests that expired caches of material in community and healthcare settings may still be efficacious substantially beyond their labeled expiration dates. History
Naloxone was patented in 1961 by Mozes J. Lewenstein, Jack Fishman, and the company Sankyo. It was approved for opioid use disorder treatment in the United States in 1971, with opioid overdose prevention kits being distributed by many states to medically untrained people beginning in 1996. From the period of 1996 to 2014, the CDC estimates over 26,000 cases of opioid overdose have been reversed using the kits.Naloxone (Nyxoid) was approved for use in the European Union in September 2017. Society and culture
Names
Naloxone is the generic name of the medication and its INN, BAN, DCF, DCIT, and JAN, while naloxone hydrochloride is its USAN and BANM.The patent has expired and it is available as a generic medication. Several of the newer formulations use patented dispensers (spray mechanisms or autoinjectors), and patent disputes over generic forms of the nasal spray were litigated between 2016 and 2020, when a judge ruled in favor of Teva, the generic manufacturer. Teva announced entry of the first generic nasal spray formulation in December 2021. Brand names of naloxone include Narcan, Kloxxado, Nalone, Evzio, Prenoxad Injection, Narcanti, Narcotan, and Zimhi, among others.
Median raphe cysts are a cutaneous condition of the penis due to developmental defects near the glans. : 682

See also
Cutaneous columnar cyst
List of cutaneous conditions


== References ==